Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4

David J. R. Foster, Andrew A. Somogyi & Felix Bochner
Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, Australia

Aims To investigate the kinetics of CYP-mediated N-demethylation of methadone in human liver microsomes, and examine the role of stereoselectivity and CYP isoforms involved.

Methods The kinetics of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) formation via N-demethylation of rac-, (R)- and (S)-methadone in human liver microsomes prepared from six liver samples were determined by h.p.l.c., and inhibition of metabolic function was studied using isoform-specific chemical inhibitors and monoclonal antibodies. Microsomes containing expressed CYP3A4, CYP2D6 and CYP2C19 were also used to examine the formation of EDDP.

Results The \( V_{\text{max}} \), \( K_{m} \), and \( C_{\text{L/min}} \) values for the formation of EDDP from rac-, (R)- and (S)-methadone were in the ranges of 20–77 nmol mg\(^{-1}\) protein h\(^{-1}\), 125–252 \( \mu \)mol, and 91–494 ml h\(^{-1}\) g\(^{-1}\) protein. \( K_{m} \) and \( C_{\text{L/min}} \) values for (R)- and (S)-methadone were not statistically significantly different (\( P > 0.05 \)), while \( V_{\text{max}} \) values for (S)-methadone were 15% (\( P = 0.045 \)) lower than for (R)-methadone. Expressed CYP3A4 and CYP2C19 showed similar reaction rates for both (R)- and (S)-methadone, while CYP2D6 did not catalyse this reaction. Selective chemical inhibitors of CYP3A (troleandomycin, ketoconazole) and monoclonal human CYP3A4 antibodies significantly inhibited (\( P < 0.05 \)) the formation of EDDP in a concentration dependent manner by up to 80%. Sulphaphenazole (CYP2C9) also significantly inhibited (\( P < 0.05 \)) EDDP formation (range 14–25%). There were no statistically significant differences in the inhibition observed between the three substrates. Selective inhibitors of CYP1A2 (furafylline), CYP2A6 (coumarin), CYP2C19 ((S)-mephenytoin), CYP2D6 (quinidine) and CYP2E1 (diethyldithiocarbamic acid sodium salt and monoclonal human CYP2E1 antibodies) had no significant (\( P > 0.05 \)) effect.

Conclusions The N-demethylation of methadone in human liver microsomes is not markedly stereoselective, and is mediated mainly by CYP3A4 with the possible involvement of CYP2C9 and CYP2C19. Thus, the large interindividual variation reported for methadone pharmacokinetics may be due to variability in the expression of these CYP isoforms, and the reported stereoselectivity in the systemic clearance of methadone in vivo is not due to stereoselectivity in N-demethylation.

Keywords: CYP3A4, EDDP formation, human liver microsomes, methadone N-demethylation, stereoselectivity

Introduction

Rac-methadone is commonly used in the management of chronic pain and as maintenance therapy for the pharmacological treatment of opioid dependence. Rac-methadone (6-dimethylamino-4,4-diphenyl-3-heptanone) is a chiral molecule (Figure 1) of (R)- and (S)-enantiomeric forms in which (R)-methadone has a 10-fold higher affinity at \( \mu \) and \( \delta \) opioid receptors [1] and possesses up to 50 times the analgesic activity of (S)-methadone in human and animal models of pain [2]. (R)-methadone has also been shown to prevent the occurrence of opioid withdrawal symptoms, while (S)-methadone is ineffective [3]. Despite this high eudismic ratio, methadone is used as the racemate in most countries. The two enantiomers differ significantly in their disposition in humans, with...
undergoes spontaneous cyclization and dehydration to form 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrroline (EDDP, Figure 1), which may then be further N-demethylated to 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP, Figure 1) [8]. p-hydroxylation of one aromatic ring has also been reported, resulting in the formation of four diastereomeric compounds collectively referred to as p-hydroxy methadone [8, 10]. After oral dosing, unchanged methadone and EDDP are found in similar amounts in the urine of humans and account for up to 50% of the dose [8, 10], with only trace amounts of EMDP; other metabolites appear to contribute relatively little to the overall metabolism of methadone [8, 10], although this has not been well studied, since complete mass balance has not been achieved.

The in vitro oxidative metabolism of (R)-methadone in human liver microsomes has only recently been described [11–14]. Iribarne and coworkers [11] reported that (R)-methadone was N-demethylated by CYP3A4, and that selective inhibitors of CYP2D6, CYP1A2, CYP2C9 had no effect. Based upon experiments with heterologously expressed CYP enzymes they did not rule out the contribution of other CYP450 isoforms. The role of stereoselectivity was not examined.

The aims of the present study were to investigate the CYP-mediated N-demethylation of methadone in human liver microsomes, and to examine the role of stereoselectivity and CYP isoforms involved in each reaction.

**Methods**

**Chemicals**

(R)-methadone as the hydrochloride salt, (R)- and (S)-methadone as the free bases (4R,6S)- and (4S,6S)-p-hydroxylated methadone (p-hydroxy methadone) as the hydroiodide salt and 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP) as the hydrochloride salt were purchased from Alltech-Applied Science Labs (State College, PA, USA). Other materials were obtained from the following sources: furafylline and (S)-mephenytoin (Ultrafine Chemicals, Manchester, England), bovine serum albumin (fraction V), butylated hydroxytoluene, chlorozoxazone, coumarin, diethylthiocarbamic acid sodium salt (DDC), DL-isocitric acid tri-sodium salt, folin-ciocalteau reagent, isocitrate dehydrogenase (NADP, type IV), quinidine sulphate, sulphaphenazole, triethylamine and troleandomycin were obtained from Sigma Chemical Company (St Louis, Mo, USA). Omeprazole was supplied by Astra Pharmaceuticals (Sydney, Australia), fluoxetine was a gift from Dr W. Hooper (Department of Pharmacology, University of New South Wales, Australia).

© 1999 Blackwell Science Ltd

Br J Clin Pharmacol, 47, 403–412
of Medicine, Royal Brisbane Hospital, Brisbane, Australia) and diazepam and ketoconazole were gifts from Professor J. Miners (Department of Clinical Pharmacology, Flinders Medical Centre, Bedford Park, Adelaide, Australia). Monoclonal antibodies to CYP3A4 and CYP2E1, and microsomes from human lymphoblastoid cells containing expressed CYP3A4, CYP2D6 and CYP2C19 were purchased from Gentest Corporation (Woburn, MA, USA). All other reagents and chemicals were obtained from commercial sources and were of analytical grade quality.

**Human liver microsomes**

Ethical approval was obtained from the Committee on the Ethics of Human Experimentation of the University of Adelaide and the Human Ethics Committee of the Royal Adelaide Hospital. All patients gave written informed consent for their liver tissue to be used. Liver tissue (HLS# 5, 16, 21, 22, 23, 31) was obtained from six patients undergoing partial hepatectomy for hepatic tumours. Donors ranged in age from 25 to 73 years, three were female and all had normal clinical chemistry and haematology prior to surgery except donor 31 with hypoalbuminaemia (33 g l\(^{-1}\)) and anaemia (haemoglobin 9.7 g l\(^{-1}\)). All tissue samples used were normal on gross morphology. Microsomes were prepared by differential centrifugation of liver homogenates [15], and total microsomal protein and cytochrome P450 content of the microsomes were quantified using the methods of Lowry and coworkers [16] and Omura & Sato [17], respectively. Liver samples and microsomal preparations were stored at −80°C until used. DNA was extracted from the liver tissue for the determination of CYP3A4 and CYP2C19 genotypes. CYP2D6 alleles screened were CYP2D6*1A, CYP2D6*4A, CYP2D6*4B, CYP2D6*4C, CYP2D6*4D and CYP2D6*5 [18, 19]. CYP2C19 alleles screened were CYP2C19*1, CYP2C19*2 and CYP2C19*3 [20]. Results of the genotyping corresponded to the extensive metaboliser phenotype for both CYP isoforms in all liver samples. Genotyping of HLS# 16 was not possible due to insufficient tissue.

**Microsomal incubations**

Incubations were performed in duplicate at 37°C in a shaking water bath for 45 min. The incubates of 200 μl final volume contained 50 mm sodium phosphate buffer (pH 7.4), NADPH generating system (1 mm NADP, 1 unit ml\(^{-1}\) isocitrate dehydrogenase, 5 mm magnesium chloride), substrate (minimum of 10 concentrations, final concentration range of 1–1500 μm for (R)- and (S)-methadone and 1–1250 μM for (R)- and (S)-methadone) and 100 μg microsomal protein. The formation of EDDP was stopped by the addition of 100 μl ice cold acetonitrile, samples were then vortexed briefly, centrifuged (10 000 g, 10 min) and a 100 μl aliquot injected on to the h.p.l.c. system. The rate of EDDP formation from 100 μM (R)- and (S)-methadone, (R)-methadone and (S)-methadone was observed to be linear up to 120 min and 400 μg microsomal protein.

**EDDP quantification**

EDDP was quantified using a reversed phase h.p.l.c. system which comprised a LC-6A pump (Shimadzu, Kyoto, Japan) at a flow rate of 1.0 ml min\(^{-1}\), a Wisp 710B autoinjector (Waters, Milford, MA, USA), a 8 × 10 Radial Compression Module (Waters) containing a 300 mm × 5 mm Noval-Pak C18 4 μm cartridge (Waters), an UV/visible 100-V spectrophotometer (Jasco, Tokyo, Japan) set at 210 nm and a C-R6A Chromatopac integrator (Shimadzu). Optimal separation of the compounds of interest was achieved with a mobile phase of 30% acetonitrile and 0.2% triethylamine in 50 mM NaH₂PO₄ with final pH adjusted to 4.3 with orthophosphoric acid. Retention times for (4R,6S)-p-hydroxy methadone, (4S,5S)-p-hydroxy methadone, EDDP, methadone, and EMDP were 3, 6, 9, 17, and 25 min, respectively. Under these conditions all compounds of interest were baseline resolved, with the exception of the p-hydroxy methadone diasteromers. In preliminary experiments, EMDP and the p-hydroxy methadone diasteromers were not observed following microsomal incubation and no further modifications to the h.p.l.c. system were attempted. Quantification of EDDP was performed with calibration curves consisting of 12 standards over the concentration range 0.25–50 μM. Inter-assay variability was monitored with quality control (QC) samples prepared in duplicate at three concentrations; low (LQC, 0.62 μM), medium (MQC, 1.74 μM) and high (HQC, 12.45 μM). Inter-assay precision (n=6) was 7.4%, 3.6% and 0.7%, while interassay inaccuracy (n=6) was −3.0%, +4.8% and −3.1% for the LQC, MQC and HQC, respectively. Similarly intra-assay precision (n=6) was 6.4%, 6.2% and 3.9%, while intra-assay inaccuracy (n=6) was −8.6%, −0.2% and −3.2% for the LQC, MQC and HQC, respectively. The assay was both precise and accurate at the limit of quantitation (0.25 μM) with coefficient of variation and inaccuracy (n=3) below 10%.

**Inhibition studies with chemical inhibitors**

Microsomes from three human liver samples (HLS# 5, 16 and 21) were used in duplicate to examine the inhibition of EDDP formation from (R)-, (R)- and (S)-methadone. Substrates were incubated at a concentration equal to their respective Kᵢ values for that
particular liver sample. Chemical inhibitors considered to be specific for various isoforms [21] were coumarin (CYP2 A6, 100 μM), DDC (CYP2E1, 100 μM and 10 μM), furafylline (CYP1A2, 100 μM), quinidine (CYP2D6, 1 μM), sulphaphenazole (CYP2C9, 100 μM), troleandomycin (CYP3A, 1, 10 and 100 μM), ketoconazole (CYP3A, 0.1, 1 and 100 μM), and (S)-mephenytoin (CYP2C19, 100 μM). In addition diazepam (CYP3A4/2C19, 100 μM [22]) and fluoxetine (CYP2D6/3A, 100 μM [23]) were also tested as they are often coadministered to individuals in methadone maintenance therapy. Chlorzoxazone (100 μM) and omeprazole (100 μM) were also tested. Incubation conditions did not alter from the kinetic study, except that the CYP enzymes were kept in ice cold until addition to the reaction mixture. Amounts of CYP enzyme used were kept constant (6 pmol P450/incubation), which resulted in amounts of protein similar to that used for the human liver microsomes (100 μg). Reaction velocities were compared to that obtained from a single human liver sample (HLS#5), which was incubated at the same time as the expressed enzyme. Substrate concentrations were fixed at 200 μM.

Secondary metabolism of EDDP

The formation of EMDP from EDDP via a second N-demethylation reaction was also examined. EDDP was incubated at a concentration of 1 mM in a single microsomal preparation under conditions identical to those used for the methadone incubations. Analysis of the sample for EMDP was performed as for the methadone incubations.

Data analysis

The rates of EDDP formation from the kinetic studies (V) were expressed as nmol mg−1 protein h−1, and Eadie-Hofstee (V/Substrate concentration vs V) plots were constructed, and a single enzyme Michaelis-Menten kinetics equation was fitted to the unweighted data using nonlinear least-squares regression analysis (Regression, Blackwell Scientific Publications, Oxford, UK) giving estimates of Vmax and Ks, where Vmax is the maximum reaction velocity and Ks is the substrate concentration at which the reaction rate is half Vmax. Intrinsic clearance (CLint) was calculated as Vmax/Ks. Rates of EDDP formation obtained from the studies with expressed CYP isoforms were expressed as pmol EDDP formed pmol−1 EDDPincubation. All data are presented as mean ± s.d. Statistically significant differences in Vmax, Ks, CLint, and percentage inhibition by the chemical inhibitors between (R)- and (S)-methadone were assessed using paired t-tests. Statistically significant differences in percentage inhibition of the chemical inhibitors compared to control reactions was assessed with one-tailed t-tests. Differences were considered significant when P<0.05.

Results

Metabolic profile

No chromatographic peaks corresponding to either of the p-hydroxy methadone diastereomers or EMDP were
observed in any incubation containing rac-, (R)- or (S)-methadone. The only metabolite observed was EDDP, whose formation was NADP-dependent, and was localized to the microsomal fraction as no EDDP formation was observed in incubations of methadone in the cytosolic liver fraction (preliminary investigations, results not shown).

Kinetics of EDDP formation

Eadie-Hofstee plots were found to be linear in all cases (Figure 2) and a single enzyme Michaelis-Menten kinetic equation was fitted to the data (Table 1). For V_{max} there was a statistically significant difference (P=0.045) between (R)-methadone and (S)-methadone (Table 1). For \( K_m \) there was a statistically significant difference (P=0.041) between (R)-methadone and rac-methadone (Table 1) and for CL_{int} there was a statistically significant difference (P=0.025) between (R)-methadone and rac-methadone (Table 1).

Inhibition with chemical inhibitors

EDDP formation from rac-, (R)-, and (S)-methadone was significantly (P<0.05) inhibited by ketoconazole at 100 \( \mu \)M (75 ± 18%, 83 ± 11%, 78 ± 4% inhibition), 1 \( \mu \)M (43 ± 12%, 43 ± 10%, 46 ± 14% inhibition) and 0.1 \( \mu \)M (8 ± 2%, 8 ± 3%, 7 ± 5% inhibition); troleandomycin at 100 \( \mu \)M (45 ± 7%, 44 ± 11%, 43 ± 10% inhibition), 10 \( \mu \)M (22 ± 11%, 19 ± 10%, 21 ± 12% inhibition); sulphaphenazole at 100 \( \mu \)M (18 ± 6%, 26 ± 4%, 14 ± 7% inhibition); DDC at 100 \( \mu \)M (44 ± 12%, 44 ± 11%, 45 ± 11% inhibition); omeprazole at 100 \( \mu \)M (29 ± 13%, 29 ± 7.3%, 23 ± 11% inhibition) and fluoxetine at 100 \( \mu \)M (56 ± 10%, 53 ± 6%, 50 ± 13% inhibition) compared with control reactions (Figure 3). In addition EDDP formation from rac-, (R)-, and (S)-methadone by microsomes prepared from HLS#31 was inhibited by both the 8 \( \mu \)l (43 ± 2% and 49 ± 1%) and 2 \( \mu \)l (20 ± 3% and 19 ± 3%) titres of the CYP3A4 specific antibodies, respectively. CYP2E1 specific antibodies did not inhibit this reaction.
Metabolism by expressed CYP isoforms

When corrected for CYP450 content, expressed CYP3A4 and CYP2C19 catalysed the \( N\)-demethylation of (R)- and (S)-methadone at similar rates, while the formation of EDDP with expressed CYP2D6 was not observed (Figure 4).

Secondary metabolism of EDDP

Incubation of EDDP at a single high concentration (1 \( \mu \text{M} \)) resulted in <1% formation of EMDP.

Discussion

Substantial interindividual variability in \( \text{rac} \)-methadone disposition has hindered its more widespread use in pain management [24] and can pose difficulties in dosage regimen designs in opioid dependence treatment. The 4–5 fold range in \( \text{CL}_{\text{int}} \) observed for the formation of EDDP from \( \text{rac} \)-, (R)-, and (S)-methadone seen in the present study was mainly a consequence of the variability in \( V_{\text{max}} \) values since the \( K_m \) values showed little intersubject variability.

To date this is the first report examining the
Lack of stereoselectivity of methadone N-demethylation

Table 1  Michaelis-Menten parameters ($V_{\text{max}}$ and $K_m$) and $\text{CL}_{\text{int}}$ for EDDP formation from $\text{S}$-, $\text{R}$-, and $\text{S}$-methadone (MD) by human liver microsomes.

<table>
<thead>
<tr>
<th>Liver sample</th>
<th>$V_{\text{max}}$ (nmol ng$^{-1}$ protein h$^{-1}$)</th>
<th>$K_m$ ($\mu$M)</th>
<th>$\text{CL}_{\text{int}}$ (ml h$^{-1}$ g$^{-1}$ protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$\text{Rac-MD}$</td>
<td>$\text{Rac-MD}$</td>
<td>$\text{S-MD}$</td>
</tr>
<tr>
<td>5</td>
<td>66</td>
<td>77</td>
<td>66</td>
</tr>
<tr>
<td>16</td>
<td>63</td>
<td>62</td>
<td>52</td>
</tr>
<tr>
<td>21</td>
<td>27</td>
<td>24</td>
<td>26</td>
</tr>
<tr>
<td>22</td>
<td>62</td>
<td>70</td>
<td>58</td>
</tr>
<tr>
<td>23</td>
<td>29</td>
<td>28</td>
<td>24</td>
</tr>
<tr>
<td>31</td>
<td>23</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>Mean</td>
<td>45</td>
<td>47</td>
<td>41*</td>
</tr>
<tr>
<td>s.d.</td>
<td>21</td>
<td>28</td>
<td>20</td>
</tr>
</tbody>
</table>

$\text{CL}_{\text{int}} = V_{\text{max}}/K_m$. Statistically significant differences compared to (R)-methadone are indicated by: *(P=0.045), ***(P=0.041), ****(P=0.025).

In the present study $p$-hydroxy methadone and EMDP were not formed, suggesting that they are likely to be minor metabolites in humans, supporting the data of Sullivan and Due [8].

CYP3A4 has been reported to be involved in the N-demethylation of $\text{S}$-methadone, although the contribution of other isoforms could not be ruled out [11, 12, 14]. Our results confirm the role of CYP3A4 in this metabolic pathway as tryptophan, ketocanazole and a selective 3A4 antibody caused concentration dependent inhibition. Approximately 20% inhibition with sulphaphenazole (100 $\mu$M) was observed indicating that CYP3C9 may also mediate this reaction, in support of Moody and coworkers [14] who reported a mean of 57% inhibition of this pathway by the same concentration of sulphaphenazole. However, ibarine and coworkers [11] found no inhibition with sulphaphenazole at 5 $\mu$M. The selective chemical inhibitors of CYP1A2, CYP2A6, CYP3C19, CYP2D6 and CYP2E1 had no effect indicating that these isoforms are unlikely to contribute substantially to EDDP formation.

Heterologously expressed human CYP450 proteins have also been examined for their ability to N-demethylate rac-methadone, and only CYP3A4 was considered to be important [11, 14]. The current results agree with those above since formation of EDDP from (R)- and (S)-methadone by microsomes from human lymphoblastoid cells containing expressed CYP3A4 at velocities comparable to those in human liver microsomes were observed. Microsomes containing expressed CYP2C19 were also found to catalyse the N-demethylation of (R)- and (S)-methadone at similar rates to expressed CYP3A4. It is unlikely that CYP2C19 plays a major role in this reaction as, total CYP2C is expressed in the human liver in amounts less than 50% of CYP3A [25, 26], no correlation was found between (S)-mephenytoin hydroxylation and rac-methadone N-demethylation reaction rates [11] and 100 $\mu$M
(S)-mephentermin, a CYP2C19 inhibitor, caused no significant inhibition of EDDP formation. 

There are several reports of either decreased methadone plasma concentrations and/or concurrent complaints of opioid withdrawal symptoms by patients soon after commencement of therapy with known CYP3A4 inducers [27–31]. The present findings confirm the involvement of CYP3A4 in the metabolism of methadone and the potential for clinically important drug–drug interactions.

Methadone has been shown to alter the metabolism of several CYP2D6 substrates in vivo and in vitro [32–35]. These results would appear to suggest that methadone is metabolized by CYP2D6. However, the results of Iribarne and coworkers [11], Moody and coworkers [14] and the present study in which quinidine, a potent CYP2D6 inhibitor, elicited no inhibition of methadone N-demethylation and expressed CYP2D6 resulted in very low EDDP formation seem to rule out the role of CYP2D6. CYP isoenzymes can have high affinity for a substrate but not metabolize the substrate (e.g. quinidine [36]). These data indicate that, although methadone is a potent inhibitor of CYP2D6, the metabolism of methadone is not mediated by this CYP isoform in humans.

There was no inhibition of EDDP formation observed when DDC was used at 10 μM, or with a CYP2E1 selective antibody. DDC inhibited the formation of EDDP from rac- (R)- and (S)-methadone by greater than 50% at 100 μM, however, this concentration is not selective for CYP2E1, and probably reflects inhibition of CYP3A4 [37]. Iribarne and coworkers [11] reported that catalytic activities of CYP2E1-mediated reactions did not correlate with rac-methadone N-demethylation, and more recently rac-methadone did not inhibit CYP2E1-mediated reactions [12]. Chlorzoxazone (100 μM) had a minimal effect on (S)-methadone N-demethylation, and no effect on rac- or (R)-methadone. These data indicate that CYP2E1 is not involved in methadone N-demethylation, and that care should be taken when selecting the concentrations of chemical inhibitors, the use of antibodies and expressed CYP isoenzymes are important in determining CYP isoform involvement. Although diazepam has been reported to competitively inhibit the metabolism of rac-methadone with a Kᵢ of 50 μM in human liver microsomes [11], the present study found no such inhibitory effect at a concentration of 100 μM. This difference in results is hard to reconcile, however, Iribarne and coworkers [11] appeared to base their results on a single liver preparation, and the influence of variation between tissue samples is one possible explanation. Our in vitro findings are consistent with two reports of no effect of diazepam on the disposition of rac-methadone in vivo [38, 39].

Fluoxetine inhibited the formation of EDDP from rac-, (R)- and (S)-methadone by 50% which is consistent with its known CYP3A4 inhibitory action [23, 40, 41]. Omeprazole was found to inhibit EDDP formation from rac-, (R)- and (S)-methadone by 30%. This is consistent with its known affinity for CYP3A4 and CYP2C19 [42–44].

In conclusion, the N-demethylation of methadone in human liver microsomes is not stereoselective, and is mediated predominantly by CYP3A4, and possibly CYP2C19 and CYP2C9 to a minor extent. Thus, the large interindividual variation reported for the pharmaco-kinetics of methadone may be due to variability in the expression of these CYP isoenzymes, and the reported stereoselectivity in the clearance of methadone in humans is not due to partial intrinsic clearance by the N-demethylation reaction.

The results were presented in part at the 29th annual meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) in December 1995.

D. J. R. Foster was a recipient of a Dawes Postgraduate Scholarship from the Royal Adelaide Hospital, Adelaide, South Australia. Funding for this research was provided by the Royal Adelaide Hospital and the University of Adelaide. The authors wish to thank the National Institute of Drug Abuse for supplying the drug compounds, and to acknowledge the contributions of Mr J. A. R. Williams, Head of the Hepatobiliary and Pancreatic Surgery Unit, Royal Adelaide Hospital, who provided the liver tissue, Ms Janet Geller of the Department of Clinical and Experimental Pharmacology, University of Adelaide, and Ms Heather James of the Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, who genotyped the liver tissue.

References
et al. 12 Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. 28 Saxon AJ, Whittaker S, Hawker CS. Valproic acid, unlike
et al. 11 Iribarne C, Berthou F, Baird S, 
10 A¨ngga˚rd E, Gunne LM, Homstrand J, McMahon RE, 26 Shimada T, Yamazaki H, Mimura M, 
© 1999 Blackwell Science Ltd
Am J Psychiatry
20 Coller JK, Somogyi AA, Bochner F. Association between the oxidation of quinidine by the sparteine/debrisoquine
9 Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz P-450 enzymes involved in the oxidation of drugs,
J Med Chem
95
methadone maintenance.
Clin Pharmacol Ther
270
414–423.

Shimada T, Yanazaki H, Mimura M, et al Characterization of microsomal cytochrome P450 enzymes involved in the
Kuhn KL, Halikas JA, Kreip KD. Carbamazepine treatment of cocaine dependence in methadone maintenance patients
Saxon AJ, Whittaker S, Hawker CS. Valproic acid, unlike other anticonvulsants, has no effect on methadone
Liu SJ, Wang RJ. Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal


Otton SV, Brinn RU, Gram LF. In vitro evidence against the oxidation of quinidine by the sparteine/3-debrisoquine

Chang TK, Gonzalez FJ, Warnan DJ. Evaluation of tranylcypromine, alpha-naphthoflavone and
Pond SM, Tong TG, Benowitz NL, Jacob PD, Rigod RJ. Measurement with the folin phenol reagent.

Toxicol in vitro properties.
Drug Metab Dispos 1993; 215–223.


Otton SV, Brinn RU, Gram LF. In vitro evidence against the oxidation of quinidine by the sparteine/3-debrisoquine

Chang TK, Gonzalez FJ, Warnan DJ. Evaluation of tranylcypromine, alpha-naphthoflavone and

Prescott KL, Griffiths RR, Cone DJ, Darwin WD, Gorodetsky CW. Diazepam and methadone blood levels following concurrent administration of diazepam and

von Molick LL, Greenblatt DJ, Coetreau Bibbo MM, Harmatz JS, Shader RJ. Inhibition of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants,


